Abstract. (±)-Pentazocine (PTZ), a non-narcotic analgesic, is used for the clinical management of moderate to severe pain. To study the effect of PTZ on the descending noradrenergic inhibitory system, in the present study we examined the effect of 
Introduction
The racemic compound (±)-pentazocine (PTZ), a non-narcotic analgesic, is used for the management of moderate to severe pain in humans. (−)-PTZ is known to act as an opioid analgesic, and (+)-PTZ is a σ-receptor agonist without analgesic effects. The antinociceptive effects of (−)-PTZ have been reported to be mediated by its agonist action at the κ-opioid receptor (1) . Although opioids remain the standard analgesics, there are clinical situations in which alternative approaches to analgesia are desired. For example, physicians are often reluctant to prescribe opioids for a chronic pain condition because of concerns about the potential for abuse and tolerance development. Additionally, opioids are of questionable effectiveness in treating some pain conditions such as neuropathic pain (2) .
Analgesia can alternatively be affected through modulation of monoamine activity with serotonin (5-HT) or norepinephrine (NE) uptake inhibitors such as amitriptyline or desipramine (3, 4) . These agents are often more effective than opioid analgesics in treating neuropathic pain (5) and are not usually associated with abuse potential. Furthermore, compounds that modify monoamine levels have been reported to modulate opioid-induced analgesia (6 -8) . In some paradigms, the interactions between opioid drugs and monoamine uptake inhibitors have been reported as additive, whereas in other models the interactions are synergistic (9, 10) .
The NE transporter (NET) is selectively expressed on NE nerve terminals, where it can exert spatial and temporal control over the action of NE (11 -13) . NET induces the termination of neurotransmission by the reuptake of NE released into the extracellular milieu. Human NET, which belongs to the gene family (SLC6A2) of sodium-and chloride-dependent neurotransmitter transporters (12, 14, 15) , was the first monoamine transporter to be cloned, and its mRNA is abundantly localized in the brain stem and adrenal medulla (11) . NET is also a critical target for various antidepressant and psychostimulants that interact with NET to increase extracellular NE by inhibiting NE uptake (11 -13) .
Adrenal medullary cells derived from the embryonic neural crest share many physiological and pharmacological properties with postganglionic sympathetic neurons. The cells express functional NET proteins (16 -18) . The pharmacological properties of NET in bovine adrenal medullary cells are similar to those of NET in central and peripheral noradrenergic neurons (13) . Therefore, NET in bovine adrenal medullary cells has provided a convenient model for studying the effects of various agents such as anesthetics and antipsychotic drugs on this transporter (19, 20) . Some centrally acting analgesic agents such as tramadol have both opioid and monoamine modes of action (21, 22) . Tramadol inhibits NET function by blocking desipramine-binding sites as the basis for its antinociceptive effect (19) . Another opioid analgesic, PTZ, has preliminarily been reported to inhibit the uptake of NE in the rat brain cortex (23) , but the precise mechanism remains unclear. In the present study, we investigated the effect of PTZ on NET activity in cultured bovine adrenal medullary cells and SK-N-SH cells and found that PTZ inhibits NET activity through suppression of its cell surface expression in an opioid receptorand σ-receptor-independent manner. Cell surface biotinylation assay was proceeded as described previously (26) . Cells in each well were solubilized by gentle shaking for 1 h in 200 μl of radioimmunoprecipitation (RIPA) buffer containing protease inhibitors (Nacalai Tesque). Cell lysates were centrifuged at 20,000 × g for 30 min, and an aliquot of each sample was used for the isolation of biotinylated proteins with streptavidin beads by incubating for 1 h at room temperature with gentle shaking. The biotinylated proteins were then washed five times with RIPA buffer and then eluted by heating the beads in sample buffer at 95°C for 5 min.
Materials and Methods

Drugs
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and western blotting were performed as follows: The NET proteins in total, nonbiotinylated and biotinylated fractions were separated by SDS-PAGE (10%), and were electroblotted onto polyvinylidene difluoride (PVDF) membrane (Immobilon-P) with transfer buffer (39 mM glycine, 48 mM Tris, 0.0375% SDS, 20% methanol, pH 8.5). After blocking with a blocking buffer (PVDF Blocking Reagent for Can Get Signal; Toyobo, Osaka) for 1 h at room temperature, the membranes were incubated with a primary antibody against NET (1:1,000; Santa Cruz Biotechnology, Calfornia, USA) or β-actin (1:10,000; Cell Signaling Technology, Beverly, MA, USA) in Can Get Signal Solution-1 (Toyobo) for 1 h at room temperature and then washed with Tris-buffered saline-Tween (10 mM Tris-HCl, pH 7.4, 150 mM NaCl and 0.1% Tween 20) (TBS-T). The immunoreactive bands were reacted in a solution (Can Get Signal Solution-2; Toyobo) with a polyclonal goat anti-rabbit antibody conjugated to horseradish peroxidase (1:10,000; Cell Signaling Technology) for 1 h at room temperature, and washed repeatedly as above. The immunoreactive bands were visualized by Immobilon Western (Millipore Corporation, Billerica, MA, USA) and quantified by Light-Capture with the CS Analyzer (ATTO Corporation, Tokyo).
COS-7 cells (RCB0539; RIKEN Cell Bank) were maintained in culture medium containing DMEM supplemented with 10% fetal bovine serum, 100 units/ml penicillin, and 100 μg/ml streptomycin. Rat serotonin transporter (rSERT) cDNA was used as previously reported (27) . Transfection of rSERT cDNA was performed using Effectene Transfection Reagent (Qiagen, Hilden, Germany) at 10:1 (reagent:cDNA) ratios. Cells were incubated after transfection for 24 to 48 h before use in the experiments. Cells (1 × 10 6 / well) were preincubated at 37°C for 20 min in KRH buffer in the presence or absence of PTZ. The cells were further incubated with KRH buffer containing 10 μM pargyline, 100 μM ascorbic acid, and [
3 H]5-HT (50 nM, 0.1 μCi) at 37°C for 12 min in the presence or absence of PTZ. Nonspecific uptake was determined in the presence of 10 μM clomipramine.
The influx of 45 Ca 2+ was measured in cultured bovine adrenal medullary cells as reported previously (24) . Cells (4 × 10 6 per dish) were incubated with 1.5 μCi of 45 CaCl 2 at 37°C for 5 min with or without 56 mM K + and PTZ in KRH buffer. After incubation, the cells were washed 3 times with ice-cold KRH buffer, solubilized in 10% Triton X-100, and the radioactivity counted.
All experiments were performed in duplicate or triplicate, and each experiment was repeated at least three times. All values are given as means ± S.E.M. Data were statistically evaluated by Student's t-test or oneway analysis of valiance (ANOVA). If a significant F value was found, Dunnett's test for multiple compari-sons was carried out to identify differences among groups. When P < 0.05, the differences were considered statistically significant.
Results
(−)-PTZ (30 μM) inhibited [
3 H]NE uptake by cultured bovine adrenal medullary cells in a time-dependent manner (Fig. 1) (Fig. 2) (Fig. 3) . Eadie-Hofstee analysis showed that both (−)-and (+)-PTZ caused a significant decrease in the maximal velocity (V max ) of [ (Fig. 4) , suggesting an opioid receptor-and σ-receptor-independent pathway. Since it is well-known that activation of protein kinase C down-regulates NET function, we examined the involvement of protein kinases in [ 3 H]NE uptake reduced by PTZ. Inhibitors of protein kinase C (calphostin C, chelerythrine, and GF109203X) did not affect the PTZ-induced inhibition of [ 3 H]NE uptake (Fig. 5) . Furthermore, H-89, an inhibitor of cAMP-dependent protein kinase, and wortmannin, a phosphoinositide 3-kinase inhibitor, also had little effect (data not shown).
To determine the site of PTZ's action on NET, we examined the effects of PTZ on the specific binding of (Fig. 7) . (−)-PTZ (1.0 -100 μM) suppressed the specific binding of [ 3 H]nisoxetine to SK-N-SH cells in a concentrationdependent manner (Fig. 8A ) similar to that of [ 3 H]NE uptake by the cells (Fig. 8B) . To examine whether (−)-PTZ-induced inhibition of [ 3 H]NE uptake or [ 3 H] nisoxetine binding occurs as a result of changes in surface expression of NETs, we determined the effect of (−)-PTZ on the population of NET proteins accessible to the membrane impermeant biotinylation reagent in human neuroblastoma SK-N-SH cells (Fig. 9) . (−)-PTZ caused a significant decrease in the ratio of density of NET band in biotinylated fractions to that of total fraction to 52.2% of the control (Fig. 9B) and to β-actin to 61.7% of the control (Fig. 9C) .
To investigate whether the inhibitory effect of PTZ on the transport function is specific for NET or not, we examined the effect of PTZ on another transporter, serotonin transporter (SERT), in rSERT cDNA transfected COS-7 cells. As shown in Fig. 10 influx (data not shown), suggesting that PTZ preferentially inhibits the function of monoamine transporters.
Discussion
PTZ, a non-narcotic analgesic with weak narcotic antagonistic activity, is advocated for the relief of moderate to severe pain. (−)-PTZ is a κ-opioid receptor agonist that induces analgesic effects, whereas (+)-PTZ is a σ-receptor agonist without analgesic effects. In addition to these receptors, we examined the effect of PTZ on NET function in adrenal medullary cells and SK-N-SH cells, a noradrenergic neuroblastoma cell line, to search for the active site of PTZ's effect on the descending noradrenergic pain modulatory pathways. In the present study, (−)-PTZ and (+)-PTZ significantly inhibited [ 3 H] NE uptake in a concentration (3.0 -100 μM)-dependent manner. The inhibitory effect of (+)-PTZ (IC 50 = 72.4 μM) was slightly less potent than that of (−)-PTZ (IC 50 = 54.6 μM). As much as 80% -90% of NE released from presynaptic terminals is believed to be physiologically taken up again by the presynaptic neurons, thereby terminating neurotransmission (12) . Therefore, even a slight inhibition of NET activity induced by PTZ may enhance noradrenergic neurotransmission.
Down-regulation of NET function by PTZ
To study the site(s) of action of PTZ on NET, we examined the effects of PTZ on kinetic parameters for NET is regulated by a number of intracellular signaling pathways. One common pathway is phosphorylation by several protein kinases such as cAMP-dependent protein kinase and protein kinase C (15, 28) . Activation of protein kinase C is reported to down-regulate the function of NET in SK-N-SH cells (29) or transfected COS-7 cells (30) . In the present study, inhibitors of protein kinase C (calphostin C, chelerythrine, and GF109203X), cAMP-dependent protein kinase (H-89), and phosphoinositide 3-kinase (wortmannin) had little effect on PTZ-induced inhibition of [ 3 H]NE uptake, suggesting that these protein kinases are not involved in the PTZ- by reducing the binding sites of [ 3 H]nisoxetine on NET. Indeed, in the present study, we observed the decrease in membrane surface expression of NET proteins after treatment with PTZ. At present, however, the intracellular mechanism of PTZ-induced down-regulation of NET remains to be clarified. This is probably due to a reduction of the membrane trafficking of NET to the plasma membrane or an increase in its degradation or endocytosis by the lysozomal degradation system. The latter possibility may partially be excluded by the sub- A) Aliquots of total and nonbiotinylated fractions were loaded, whereas the entire eluate from streptavidin beads was loaded as the biotinylated sample and blots were probed with NET antibody as described. B, C) Data are means ± S.E.M. of three separate experiments and are expressed as % of the control NET band [the ratio of the density of biotinylated NET fraction (54 kDa) to that of total NET] (B) and as % of the control (the ratio of the density of biotinylated NET fraction to that of β-actin) (C). *P < 0.05, compared with the control. sequent finding that bafilomycin A1, a lysosomal inhibitor, did not reverse the inhibition of [ 3 H]NE uptake induced by PTZ (data not shown). Further study will be required to determine the mechanism by which PTZ down-regulates NET function.
The pharmacological significance of PTZ-induced downregulation of NET
After intramuscular administration of 40 or 80 mg of PTZ, mean peaks of PTZ plasma concentration at 15 min were 102 and 227 ng/ml (0.318 and 0.707 μM), respectively (31) . In the present study, the [ 3 H]NE uptake in adrenal medullary cells was significantly inhibited by PTZ at 3.0 -100 μM, and the specific binding of [ 3 H] nisoxetine and [ 3 H]NE uptake of intact SK-N-SH cells were significantly inhibited by PTZ at 1 -100 μM and 3.0 -100 μM, respectively. Taken together, the present findings and previous data suggest that near-clinical concentrations of PTZ partly suppress the NET function of cultured bovine adrenal medullary cells.
Several lines of evidence have shown that the descending inhibitory system consists of noradrenergic and/or serotonergic neurons (32, 33) . A recent study reported a potential use of 5-HT 7 receptor agonists as adjuvants of opioid analgesia because spinal activation of 5-HT 7 receptors has a role in the expression of opiateinduced analgesia through activation of descending inhibition (34) . Furthermore, the antinociceptive effects of some clinical drugs, such as tricyclic antidepressants, are partially explained by enhanced noradrenergic or serotonergic neurotransmission induced by suppression of the NET or SERT in the descending inhibitory system in the brain and spinal cord (35) . Indeed, in the present study, PTZ inhibited not only NET function but also SERT function, suggesting a preferential inhibition by PTZ of monoamine transporter functions. Furthermore, several anesthetics such as ketamine and propofol also inhibited the NET function (36, 37) . Taken together with these results, it is intriguing to propose that PTZ induces antinociceptive effects via the down-regulation of NET and/or SERT in addition to the activation of opioid receptors.
Readers assessing the significance of the present findings should bear in mind the limitations of this study. First, the cellular mechanism by which PTZ induces the down-regulation of NET function has not been elucidated. Further investigations, including those on NET membrane trafficking and internalization or degradation, are needed to clarify its molecular mechanism after exposure to PTZ. Second, although cultured bovine adrenal medullary cells or SK-N-SH cells are a good in vitro model system of noradrenergic neurons, in vivo animal studies of PTZ are required to establish the involvement of NET down-regulation by PTZ in its antinociceptive effect.
In conclusion, the present findings suggest that near-clinical concentrations of PTZ induce the downregulation of NET via suppression of cell surface expression of NET proteins. This may add a new antinociceptive aspect of PTZ to our pharmacological understanding of analgesics.
